Published: March 2023
Over time, therapeutic vaccines have generated significant interest in the pharmaceutical industry owing to their safety, specificity, augmented immunity and long-term clinical benefits in the treatment of chronic infections and various types of cancer
Given that therapeutic vaccines intend to alleviate the suffering of the patient already infected with disease, it is being used as an effective therapy to treat diseases like cancer, HIV and many more prevalent concerns across the globe. It is efficious in treating individuals who are affected with chronic infections but cannot produce enough efficient antibodies.
To order this 350+ page report, which features 90+ figures and 100+ tables, please visit this link
Presently, 350+ therapeutic vaccines have been / are being evaluated across different phases of development for the treatment of various disease indications
Close to 88% of the pipeline candidates are under clinical evaluation and therapeutics, namely Provenge®, Copaxone® and RIAVAX® have been approved for the treatment of prostate cancer, multiple sclerosis and pancreatic cancer respectively. Majority (71%) of these candidates are used for the treatment of oncological disorders, followed by treatment of infectious diseases (9%).
More than 700 clinical trials have been registered for the evaluation of therapeutic vaccines, worldwide
The clinical research activity, in terms of number of trials registered, is reported to have increased at a CAGR of 27%, during the period 2019-2021. Of the total number of trials registered, close to 54% have already been completed, while 18% of the studies are actively recruiting participants.
Over 500 grants have been awarded to support the development of therapeutic vaccines, since 2016
Grants worth USD 467 million have been awarded to various organizations working in this domain during the period, 2016- 2022. Of these, 51% of the grants were awarded to support the research related to projects on therapeutic vaccines, were / are being managed by NIAID, followed by those managed by NCI (30%) and NIDA (4%).
Partnership activity within this domain has increased at a CAGR of 6%, between 2018 and 2020
More than 35% of the reported deals were established since 2020, with the maximum activity (~50%) being reported in 2020. Majority of the partnerships were product development and commercialization agreements (27%), followed by clinical trial agreements (23%).
Over 20 start-ups have emerged in the last 10 years in the therapeutic vaccines domain
Over 57% of the start-ups were established in Europe. Among these, more than 25% of the firms are based in France. This is followed by North America, accounting for more than 38% of the start-ups focused on therapeutic vaccines.
North America is anticipated to capture larger share of the market by 2035
In terms of type of vaccine, the major share is captured by dendritic vaccines in the year 2022; this trend is unlikely to change in the foreseen future. Further, among therapeutic areas, vaccines targeting oncological disorders hold the larger market share.
To request a sample copy / brochure of this report, please visit this link
The financial opportunity within the therapeutic vaccines market has been analysed across the following segments:
The report includes profiles of key players (listed below) engaged in the development of therapeutic vaccines; each profile features a tabulated overview of company, product portfolio, recent developments, and an informed future outlook.
For additional details, please visit https://www.rootsanalysis.com/reports/global-therapeutic-vaccines-market.html or email firstname.lastname@example.org
You may also be interested in the following titles:
+1 (415) 800 3415
+44 (122) 391 1091
We are your partners with no equity
We fit in your budget
We love what we do
Chance to prove ourselves
Best in class quality of work
Most trusted consulting partner in the industry
SUBSCRIBE TO INDUSTRY UPDATES